Stocktoria
BICYCLE THERAPEUTICS PLC BCYC
BICYCLE THERAPEUTICS PLC (BCYC) earns a Piotroski F-score of 1/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $72.6M at a -301.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 1/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.872 |
| Retained earnings / assets | -1.254 |
| EBIT / assets | -0.344 |
| Equity / liabilities | 5.668 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| BCYC | BICYCLE THERAPEUTICS PLC | 1/9 | 5.27 | — | +105.8% |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | 3/9 | -1.34 | — | +153.5% |
| VRDN | Viridian Therapeutics, Inc.DE | 2/9 | 2.72 | — | — |
| ABCL | AbCellera Biologics Inc. | 4/9 | 4.67 | — | +160.6% |
| RMTI | ROCKWELL MEDICAL, INC. | 2/9 | -18.33 | — | -31.8% |
| CTMX | CytomX Therapeutics, Inc. | 1/9 | -10.12 | — | -44.8% |
| KURA | Kura Oncology, Inc. | 2/9 | -2.37 | — | +25.2% |
About BICYCLE THERAPEUTICS PLC
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
FAQ
Is BCYC financially healthy?
BICYCLE THERAPEUTICS PLC's Piotroski F-score is 1/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does BCYC pay a dividend?
No, BICYCLE THERAPEUTICS PLC does not currently pay a dividend.
How profitable is BCYC?
In FY2025, BICYCLE THERAPEUTICS PLC had a net margin of -301.7% and a return on equity of -35.9%.
What is the analyst price target for BCYC?
The average Wall-Street price target for BICYCLE THERAPEUTICS PLC is $12.62, about 211.0% above the recent price, from 8 analysts (consensus: buy).
Is BCYC a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on BICYCLE THERAPEUTICS PLC: a Piotroski F-score of 1/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.